Monopar Therapeutics Inc
Company Profile
Business description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Contact
1000 Skokie Boulevard
Suite 350
WilmetteIL60091
USAT: +1 847 388-0349
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.00 | 59.20 | -0.66% |
| CAC 40 | 8,115.75 | 7.66 | -0.09% |
| DAX 40 | 25,372.35 | 38.28 | -0.15% |
| Dow JONES (US) | 51,365.21 | 146.38 | -0.28% |
| FTSE 100 | 10,727.42 | 22.16 | 0.21% |
| HKSE | 24,761.13 | 72.99 | -0.29% |
| NASDAQ | 26,786.57 | 149.47 | -0.55% |
| Nikkei 225 | 65,513.99 | 495.04 | 0.76% |
| NZX 50 Index | 13,824.83 | 3.07 | 0.02% |
| S&P 500 | 7,690.76 | 15.27 | -0.20% |
| S&P/ASX 200 | 8,702.00 | 63.30 | -0.72% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |